Investor Alert

Market Pulse Archives

June 27, 2016, 4:30 p.m. EDT

Regulus Therapeutics' stock set to fall after FDA places hepatitis C treatment on hold

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regulus Therapeutics Inc. (RGLS)
  • X
    SPDR S&P Biotech ETF (XBI)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Regulus Therapeutics Inc. /zigman2/quotes/202916513/composite RGLS -12.64% were set to sell off in after-hours trade Monday, after the biopharmaceutical company said the Food and Drug Administration placed its investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold. The stock was halted for news, and is scheduled to being trading again at 4:40 p.m. ET. Regulus said the FDA initiated the clinical hold after a second serious adverse event of jaundice was reported. Regulus said it expects to receive a formal letter from the FDA within 30 day, and plans to work with the FDA as it seeks a release of the clinical hold. The stock had plunged 43% year to date through Monday, while the SPDR S&P Biotech ETF /zigman2/quotes/205950134/composite XBI -2.76% has lost 29% and the S&P 500 has slipped 2.1%.

US : U.S.: Nasdaq
$ 1.52
-0.22 -12.64%
Volume: 96,983
Dec. 6, 2022 3:59p
P/E Ratio
Dividend Yield
Market Cap
$29.30 million
Rev. per Employee
US : U.S.: NYSE Arca
$ 80.59
-2.29 -2.76%
Volume: 9.20M
Dec. 6, 2022 4:00p

Get news alerts on Regulus Therapeutics Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.